Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $670.8 million.

  • Mirum Pharmaceuticals' Liabilities and Shareholders Equity rose 17.55% to $785.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 9.31%. This contributed to the annual value of $670.8 million for FY2024, which is 3.73% up from last year.
  • According to the latest figures from FY2024, Mirum Pharmaceuticals' Liabilities and Shareholders Equity is $670.8 million, which was up 3.73% from $646.6 million recorded in FY2023.
  • Mirum Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $670.8 million for FY2024, and its period low was $240.9 million during FY2020.
  • Over the past 3 years, Mirum Pharmaceuticals' median Liabilities and Shareholders Equity value was $646.6 million (recorded in 2023), while the average stood at $556.8 million.
  • Data for Mirum Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY spiked of 83.23% (in 2023) over the last 5 years.
  • Mirum Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $240.9 million in 2020, then increased by 22.33% to $294.7 million in 2021, then increased by 19.77% to $352.9 million in 2022, then spiked by 83.23% to $646.6 million in 2023, then rose by 3.73% to $670.8 million in 2024.